Newron Pharmaceuticals SpA (0QOI) Stock Statistics & Valuation Metrics

Newron Pharmaceuticals SpA has a market cap or net worth of CHF 191.15M. The enterprise value is CHF 273.34M.

Market Cap

CHF 191.15M

Enterprise Value

CHF 273.34M

Newron Pharmaceuticals SpA has 21,238,867 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

21,238,867

Owned by Insiders

―

Owned by Institutions

0.97%

Newron Pharmaceuticals SpA’s return on equity (ROE) is 1.19 and return on invested capital (ROIC) is -17.02%.

Return on Equity (ROE)

1.19

Return on Assets (ROA)

-0.33

Return on Invested Capital (ROIC)

-17.02%

Return on Capital Employed (ROCE)

0.47

Revenue Per Employee

708.37K

Profits Per Employee

-490.33K

Employee Count

27

Asset Turnover

0.48

Inventory Turnover

0.00

The current PE Ratio of Newron Pharmaceuticals SpA is -6.70. Newron Pharmaceuticals SpA’s PEG ratio is 0.07.

PE Ratio

-6.70

PS Ratio

19.20

PB Ratio

-17.12

Price to FCF

-16.56

Price to Operating Cash Flow

-16.66

PEG Ratio

0.07

In the last 12 months, Newron Pharmaceuticals SpA had revenue of 19.13M and earned -13.24M in profits. Earnings per share was -0.67.

Revenue

19.13M

Gross Profit

19.13M

Operating Income

-4.70M

Pretax Income

-12.35M

Net Income

-13.24M

EBITDA

-4.55M

Earnings Per Share (EPS)

-0.67

In the last 12 months, operating cash flow was -12.04M and capital expenditures -36,628, giving a free cash flow of -12.07M billion.

Operating Cash Flow

-12.04M

Free Cash Flow

-12.07M

Free Cash Flow per Share

-0.59

Newron Pharmaceuticals SpA pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-6.04%

Earnings Yield

-14.70%

Beta

1.84

52-Week Price Change

-37.50%

50-Day Moving Average

10.01

200-Day Moving Average

13.65

Relative Strength Index (RSI)

50.71

Average Volume (3m)

3,906

Newron Pharmaceuticals SpA upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).

Last Earnings Date

Sep 22, 2026

Next Earnings Date

Mar 16, 2027

Ex-Dividend Date

―

Newron Pharmaceuticals SpA as a current ratio of 0.76, with Debt / Equity ratio of -342.73%

Current Ratio

0.76

Quick Ratio

0.76

Debt to Market Cap

0.07

Net Debt to EBITDA

-5.70

Interest Coverage Ratio

-1.06

In the past 12 months, Newron Pharmaceuticals SpA has paid 885.00K in taxes.

Income Tax

885.00K

Effective Tax Rate

-0.07

Newron Pharmaceuticals SpA EV to EBITDA ratio is -9.95, with an EV/FCF ratio of -18.46.

EV to Sales

21.41

EV to EBITDA

-9.95

EV to Free Cash Flow

-18.46

EV to Operating Cash Flow

-18.52

Newron Pharmaceuticals SpA has CHF 32.99M in cash and marketable securities with CHF 39.16M in debt, giving a net cash position of -CHF 6.17M billion.

Cash & Marketable Securities

CHF 32.99M

Total Debt

CHF 39.16M

Net Cash

-CHF 6.17M

Net Cash Per Share

-CHF 0.29

Tangible Book Value Per Share

-CHF 0.57

Gross margin is 100.03%, with operating margin of -216.76%, and net profit margin of -283.10%.

Gross Margin

100.03%

Operating Margin

-216.76%

Pretax Margin

-274.68%

Net Profit Margin

-283.10%

EBITDA Margin

-215.09%

EBIT Margin

-216.76%

The average price target for Newron Pharmaceuticals SpA is CHF 24.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

CHF 24.50

Price Target Upside

173.13% Upside

Analyst Consensus

Moderate Buy

Analyst Count

2

Revenue Growth Forecast

-82.88%

EPS Growth Forecast

-212.48%